Kazia Therapeutics Partners on Innovative PD-L1 Degrader for Cancer Immunotherapy Development

Kazia Therapeutics Partners for Groundbreaking Cancer Immunotherapy Development

Kazia Therapeutics Limited has recently entered an exclusive collaboration and in-licensing agreement with QIMR Berghofer, focusing on a pioneering PD-L1 degrader program led by the compound NDL2. This innovative approach aims to tackle the significant challenge of cancer cells evading immune responses, a critical barrier in effective cancer treatment. PD-L1, a protein frequently expressed by tumors, binds to PD-1 receptors on T cells, effectively paralyzing the immune response. While traditional therapies have employed monoclonal antibodies to block PD-L1 from interacting with PD-1, many patients experience resistance, leading to treatment failures. Kazia’s NDL2 seeks to disrupt this cycle by specifically degrading modified forms of PD-L1 that facilitate tumor progression and contribute to immunotherapy resistance.

The significance of NDL2 lies in its unique mechanism of action, which utilizes a bicyclic peptide degrader developed by Professor Sudha Rao. This compound leverages the cell's natural protein disposal systems to eliminate resistant PD-L1 forms from various cellular compartments. By doing so, NDL2 aims to restore immune functionality and re-activate T-cells within the tumor microenvironment. Preclinical studies demonstrate the efficacy of NDL2 in reducing tumor growth in aggressive triple-negative breast cancer (TNBC) models, whether used alone or in combination with other anti-PD-1 therapies. Notably, these studies also indicate that NDL2 does not exhibit toxicity, making it a promising candidate for further development.

Kazia is currently focusing its development efforts on advanced breast cancer, with plans to optimize NDL2’s stability, potency, pharmacokinetics, and pharmacodynamics in collaboration with top oncology peptide manufacturers. This targeted strategy not only addresses the urgent needs of primary non-responders and patients who have relapsed but also holds the potential for achieving durable immune responses against tumors. As the collaboration progresses, Kazia’s innovative approach could revolutionize treatment paradigms for patients who have limited options in combating aggressive forms of cancer.

In addition to its focus on NDL2, Kazia continues to explore advancements in the field of oncology. The collaboration with QIMR Berghofer marks a significant step in the company’s commitment to developing novel immunotherapies that address unmet medical needs within oncology. This partnership highlights the increasing importance of innovative strategies to overcome resistance in cancer treatments, a growing concern in the medical community as the landscape of cancer therapy evolves.

With this collaboration, Kazia Therapeutics positions itself at the forefront of cancer research, aiming to deliver transformative therapies that can enhance the effectiveness of immunotherapy and improve patient outcomes.